- Home
- IRMD vs ABUS Comparison
IRMD vs ABUS Comparison
Compare IRMD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- ABUS
- Stock Information
- Founded
- IRMD 1992
- ABUS 2005
- Country
- IRMD United States
- ABUS United States
- Employees
- IRMD N/A
- ABUS N/A
- Industry
- IRMD Medical/Dental Instruments
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- ABUS Health Care
- Exchange
- IRMD Nasdaq
- ABUS Nasdaq
- Market Cap
- IRMD 662.5M
- ABUS 592.8M
- IPO Year
- IRMD 2014
- ABUS N/A
- Fundamental
- Price
- IRMD $51.77
- ABUS $3.15
- Analyst Decision
- IRMD Strong Buy
- ABUS Strong Buy
- Analyst Count
- IRMD 1
- ABUS 4
- Target Price
- IRMD $72.00
- ABUS $5.50
- AVG Volume (30 Days)
- IRMD 39.3K
- ABUS 1.3M
- Earning Date
- IRMD 05-01-2025
- ABUS 05-01-2025
- Dividend Yield
- IRMD 1.32%
- ABUS N/A
- EPS Growth
- IRMD 11.11
- ABUS N/A
- EPS
- IRMD 1.50
- ABUS N/A
- Revenue
- IRMD $73,242,121.00
- ABUS $6,171,000.00
- Revenue This Year
- IRMD $10.58
- ABUS $14.57
- Revenue Next Year
- IRMD $17.74
- ABUS $15.84
- P/E Ratio
- IRMD $34.51
- ABUS N/A
- Revenue Growth
- IRMD 11.71
- ABUS N/A
- 52 Week Low
- IRMD $40.18
- ABUS $2.63
- 52 Week High
- IRMD $63.29
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- IRMD 47.77
- ABUS 46.31
- Support Level
- IRMD $50.63
- ABUS $2.71
- Resistance Level
- IRMD $53.06
- ABUS $3.34
- Average True Range (ATR)
- IRMD 2.35
- ABUS 0.22
- MACD
- IRMD 0.22
- ABUS -0.01
- Stochastic Oscillator
- IRMD 64.81
- ABUS 48.89
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.